Bristol-Myers Squibb(US:BMY) ZACKS·2025-07-22 22:46Company Performance - Bristol Myers Squibb (BMY) ended the recent trading session at $48.02, demonstrating a +2.85% change from the preceding day's closing price, outperforming the S&P 500 which registered a daily gain of 0.06% [1] - The stock has fallen by 0.49% in the past month, leading the Medical sector's loss of 1.83% and undershooting the S&P 500's gain of 5.88% [1] Earnings Forecast - The company is scheduled to release its earnings on July 31, 2025, with a predicted EPS of $1.17, indicating a 43.48% decline compared to the equivalent quarter last year [2] - The consensus estimate projects a revenue of $11.33 billion, reflecting a 7.1% fall from the equivalent quarter last year [2] Full Year Estimates - For the full year, the Zacks Consensus Estimates project earnings of $6.37 per share and a revenue of $46.26 billion, demonstrating changes of +453.91% and -4.23%, respectively, from the preceding year [3] Analyst Estimates - Recent modifications to analyst estimates for Bristol Myers Squibb indicate the ever-changing nature of near-term business trends, with positive estimate revisions being a sign of optimism about the business outlook [4] Zacks Rank and Valuation - The Zacks Rank system currently holds Bristol Myers Squibb at 3 (Hold), with the Zacks Consensus EPS estimate having moved 5.7% lower within the past month [6] - The company has a Forward P/E ratio of 7.33, indicating a discount compared to its industry's Forward P/E of 17.79 [7] PEG Ratio - Bristol Myers Squibb currently trades at a PEG ratio of 2.44, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.47 [8] Industry Ranking - The Medical - Biomedical and Genetics industry is part of the Medical sector, holding a Zacks Industry Rank of 95, placing it in the top 39% of all 250+ industries [9]